Sponsor:
Bristol-Myers Squibb
Code:
NCT07772531
Conditions
Major Depressive Disorder
Eligibility Criteria
Sex: All
Age: 18 - 65
Healthy Volunteers: Not accepted
Interventions
BMS-986511
Placebo
Brief summary:
Conditions
Major Depressive Disorder
Study ID
NCT07772531
Start date
Oct 30, 2026
Status verified date
Nov, 2026
Completion date
Nov 6, 2028
Anticipated
Primary completion date
Nov 6, 2028
Anticipated
Eligibility Criteria
Sex: All
Age: 18 - 65
Healthy Volunteers: Not accepted
Enrollment
200 participants
Anticipated
Allocation
Randomized
Intervention Model
Sequential
Primary purpose
Treatment
Arms
experimental: BMS-986511: Dose A
experimental: BMS-986511: Dose B
experimental: Placebo
Interventions
BMS-986511
Placebo
Primary outcome measure
Central contacts
Locations
Woodland International Research Group
Recruiting
Little Rock, Arkansas, United States, 72211
Contacts
George Konis, Site 0038
501-221-8681Woodland Research Northwest LLC
Recruiting
Rogers, Arkansas, United States, 72758
Contacts
Ryan Mahelona, Site 0047
479-927-3000CenExel CBH
Recruiting
Atlanta, Georgia, United States, 30331
Contacts
Elyssa Barron, Site 0140
404-881-5800Sponsor
Bristol-Myers Squibb
Last update posted
Nov 18, 2026
Last verified
Nov, 2026
Keywords
Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-19. This information was provided to ClinicalTrials.gov by Bristol-Myers Squibb on 2026-11-18. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.